Glycorex Transplantation AB (GTAB B) – publication of Annual Report 2020

Report this content

Today Glycorex Transplantation AB (publ) publishes the Annual Report for 2020 (in Swedish only). The Annual Report is attached to this press release and is also available on

This disclosure contains information that Glycorex Transplantation is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on April 21 at 18:15 CET.

For further information, please contact:

Pontus Nobréus, CEO, Glycorex Transplantation AB
e-mail:, phone: +46 46-286 52 30

Optimizing blood for life – solutions for improved quality of life and better health economy

Glycorex’s unique molecular level technology that specifically selects and removes antibodies in the blood has opened up ground-breaking treatments and solutions in healthcare. The company’s medical devices enable transplants across the blood groups saving lives and providing health economic benefits by increasing the number of transplants. The company’s technology to treat blood is applied in several health care settings and a new disruptive product has recently been launched with the potential to increase availability of blood plasma. Several new products for the treatment of autoimmune diseases are under development.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.